AQP1 and central nervous system cancer: In gliomas, both AQP1 and AQP4, when suppressed, offer a better prognosis for patients affected by these types of tumors by edema reduction (Faraj et al., 2022; Ohmura et al., 2023), facilitating the management of neurological deficits in the pre-and postoperative periods, with peritumoral edema being more relevant, in terms of concerns the aggressiveness of this cancer, rather than its extent, per se (Faraj et al., 2022).